Microvascular Disease
6
1
1
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
16.7%
1 terminated out of 6 trials
66.7%
-19.8% vs benchmark
17%
1 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (6)
Test of Reproducibility of [15O]H20-PET Assessment of Brain Perfusion
Comparison of Differencens in VO2-max, Perfusion of the Heart and Brain and Cognitive Performance Between Patients with Type 2 Diabetes and Healthy Age Matched Controls.
Macrovascular and Microvascular Morbidity and Mortality After Metabolic Surgery Versus Medicines
MICRO: a Registry Study in Patients With Microvascular Angina
Hyperoxia and Microvascular Dysfunction
The Vascular Effects of Vildagliptin in Insulin Resistant Individuals